文献速递前列腺增生与排尿功能障碍泌尿系感染小儿泌尿与泌尿修复

外尿道括约肌肉毒毒素注射治疗脑性瘫痪患者的假性协同失调

External Urethral Sphincter Botulinum Toxin Injection to Treat Pseudodysynergia in Patients With Cerebral Palsy.
PubMed 文献 · Urology · 2024-02-20

该回顾性队列研究纳入2016至2023年间接受尿道外括约肌onabotulinumtoxinA(BTX)注射的50例成人脑性瘫痪患者,主要适应证为尿潴留(96%)、下尿路症状(48%)、肾积水(18%)和反复尿路感染(22%)。注射后下尿路症状改善67%、尿潴留改善65%、肾积水改善67%、反复尿路感染改善73%,60%患者接受重复注射,无显著并发症。作者认为外尿道括约肌BTX注射是治疗成人脑性瘫痪假性协同失调的安全有效选择。

要点

  • 成人脑性瘫痪患者因外尿道括约肌痉挛可出现假性协同失调,导致膀胱出口梗阻和尿潴留。
  • 外尿道括约肌BTX注射后下尿路症状改善67%、尿潴留改善65%、肾积水改善67%、反复尿路感染改善73%。
  • 60%患者接受重复注射,无显著注射相关并发症。

核心结论

  • 外尿道括约肌BTX注射是治疗成人脑性瘫痪假性协同失调的安全有效选择。

研究设计与样本

  • 回顾性队列研究,纳入2016至2023年间接受尿道外括约肌BTX注射的50例成人脑性瘫痪患者。
  • 手术采用100 U或200 U BTX混合于4 mL生理盐水。
  • 主要结局为患者或照护者报告的主观尿潴留、下尿路症状、反复尿路感染频率变化,以及超声所示肾积水或膀胱结石/碎屑。

主要发现

  • 50例患者中男性占60%,58%居家并由他人协助生活,50%为粗大运动功能分类系统V级(即严重脑性瘫痪)。
  • BTX注射最常见适应证为尿潴留(96%)、下尿路症状(48%)、肾积水(18%)和反复尿路感染(22%)。
  • 注射后下尿路症状改善67%、尿潴留改善65%、肾积水改善67%、反复尿路感染改善73%。
  • 60%患者接受重复注射,无显著注射相关并发症。

临床怎么用

  • 作者认为外尿道括约肌BTX注射是治疗成人脑性瘫痪假性协同失调的安全有效选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate urinary outcomes following cystoscopic external urinary sphincter onabotulinumtoxinA (BTX) injections in patients with cerebral palsy (CP). Adults with CP can suffer from bladder outlet obstruction and urinary retention due to a spastic external urethral sphincter ("pseudodysynergia"). We have used BTX injections into the sphincter to relieve the obstruction and allow patients to maintain spontaneous voiding rather than intermittent catheterization. METHODS: Patients were included in this retrospective cohort study if they had a diagnosis of CP, were at least 18 years of age, and underwent a urethral external sphincter BTX injection between 2016-2023. The procedure included 100 u or 200 u of BTX mixed in 4cc of saline. Primary outcomes were subjective, patient or caregiver reported changes in retention, lower urinary tract symptoms (LUTS), frequency of recurrent urinary tract infections (UTIs), and hydronephrosis or bladder stones/debris on ultrasound. RESULTS: Fifty patients were included; the majority were male (60%), lived at home with assistance (58%), and had a Gross Motor Function Classification System level of V (50%; ie, severe CP). The most common indications for BTX were retention (96%), LUTS (48%), hydronephrosis (18%), and recurrent UTIs (22%). Post-BTX improvement was seen in 67% of those with LUTS, 65% with retention, 67% with hydronephrosis, and 73% with recurrent UTIs. Most patients underwent repeat injections (60%). There were no significant complications associated with injections. CONCLUSION: External urethral sphincter BTX is a safe, effective option for treating pseudodysynergia in adults with CP.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Haggart R, Loftus CJ, DeWitt-Foy M, et al. External Urethral Sphincter Botulinum Toxin Injection to Treat Pseudodysynergia in Patients With Cerebral Palsy. Urology. 2024. PMID: 38387511. doi:10.1016/j.urology.2023.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。